OTCMKTS:APLIF

Appili Therapeutics - APLIF Stock Forecast, Price & News

$0.04

0.00 (0.00%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.04
▼
$0.04
50-Day Range: $0.04
▼
$0.06
52-Week Range: $0.04
▼
$0.90

Volume: N/A
Average Volume: 32,015 shs
Market Capitalization: $2.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Appili Therapeutics (OTCMKTS:APLIF) Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

September 22, 2022 | finance.yahoo.com

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

August 12, 2022 | finance.yahoo.com

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

August 2, 2022 | finance.yahoo.com

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

July 14, 2022 | finance.yahoo.com

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

July 1, 2022 | seekingalpha.com

Appili Therapeutics GAAP EPS of -C$0.38

June 29, 2022 | finance.yahoo.com

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

May 26, 2022 | finance.yahoo.com

Appili Therapeutics Announces Closing of Public Offering of $4,500,000

May 18, 2022 | seekingalpha.com

Appili Therapeutics launches securities offering

April 27, 2022 | finance.yahoo.com

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2022 | finance.yahoo.com

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

March 29, 2022 | finance.yahoo.com

Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings

March 9, 2022 | finance.yahoo.com

Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum

March 8, 2022 | finance.yahoo.com

UPDATE – Life Sciences Investor Forum: Company Executives Present Live March 10th

March 3, 2022 | finance.yahoo.com

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

February 28, 2022 | seekingalpha.com

Appili to get $10M from US DOD to advance potential biodefense vaccine ATI-1701

February 28, 2022 | finance.yahoo.com

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

February 14, 2022 | finance.yahoo.com

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

February 8, 2022 | finance.yahoo.com

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

December 28, 2021 | finance.yahoo.com

Aditxt Signs Share Exchange Agreement to Acquire AiPharma

December 23, 2021 | finance.yahoo.com

Appili Therapeutics – Press Release Correction

December 23, 2021 | finance.yahoo.com

Appili Therapeutics – Press Release Correction

December 22, 2021 | finance.yahoo.com

Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners

December 11, 2021 | realmoney.thestreet.com

Appili Therapeutics Inc Class A

November 29, 2021 | finance.yahoo.com

APLIF: PRESECO Trial Unsuccessful in COVID-19…

November 19, 2021 | finance.yahoo.com

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Company Calendar

Today: 10/04/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:APLIF
CUSIP: N/A
CIK: N/A
Web: www.appilitherapeutics.com
Phone: 902-442-4655
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,040,000.00
Net Margins: N/A
Pretax Margin: -1,417.91%
Return on Equity: N/A
Return on Assets: -207.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.99
Quick Ratio: 1.99

Sales & Book Value

Annual Sales: $1.11 million
Price / Sales: 2.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -0.98

Miscellaneous

Outstanding Shares: 71,270,000
Free Float: N/A
Market Cap: $2.78 million
Optionable: Not Optionable
Beta: -0.70

Key Executives

Dr. Armand Balboni J.D. (Age 56)
M.D., Ph.D., CEO & Director
Comp: $279.7k

Dr. Yoav Golan M.S. (Age 60)
M.D., MS, Chief Medical Officer
Comp: $248.56k

Dr. Donald D. Cilla Jr.
M.B.A., Pharm.D., Pharmd, Chief Devel. Officer

Mr. Kenneth G. Howling
Acting Chief Financial Officer

Key Competitors

View All Competitors

APLIF Stock - Frequently Asked Questions

Should I buy or sell Appili Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Appili Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" APLIF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APLIF, but not buy additional shares or sell existing shares.
View APLIF analyst ratings or view top-rated stocks.
How have APLIF shares performed in 2022?: Appili Therapeutics' stock was trading at $0.09 at the beginning of 2022. Since then, APLIF stock has decreased by 56.7% and is now trading at $0.0390.
View the best growth stocks for 2022 here.
Are investors shorting Appili Therapeutics?: Appili Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 78,200 shares, a decrease of 33.2% from the August 31st total of 117,100 shares. Based on an average daily volume of 46,100 shares, the short-interest ratio is presently 1.7 days.
View Appili Therapeutics' Short Interest.
When is Appili Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APLIF earnings forecast.

What is Appili Therapeutics' stock symbol?: Appili Therapeutics trades on the OTCMKTS under the ticker symbol "APLIF."
How do I buy shares of Appili Therapeutics?: Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Appili Therapeutics' stock price today?: One share of APLIF stock can currently be purchased for approximately $0.04.
How much money does Appili Therapeutics make?: Appili Therapeutics (OTCMKTS:APLIF) has a market capitalization of $2.78 million and generates $1.11 million in revenue each year. The company earns $-20,040,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.
How can I contact Appili Therapeutics?: Appili Therapeutics' mailing address is 21-1344 SUMMER ST., HALIFAX A5, B3H 0A8. The official website for the company is www.appilitherapeutics.com. The company can be reached via phone at 902-442-4655.

This page (OTCMKTS:APLIF) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms